SEC Form 4 · accession 0001209191-15-081517

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 18, 2015

Accepted (ET)

Nov 20, 2015 · 4:08 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Nov 18, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Nov 18, 2015	S	2,800	$128.96	D	352,884	D
Common Stock^F2,F4	Nov 18, 2015	S	800	$130.25	D	352,084	D
Common Stock^F2,F5	Nov 18, 2015	S	3,100	$131.55	D	348,984	D
Common Stock^F2,F6	Nov 18, 2015	S	3,300	$132.44	D	345,684	D
Common Stock^F2,F7	Nov 18, 2015	S	400	$133.03	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$35.64	Nov 18, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	104,800	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $128.96 (range $128.71 to $129.52).
F4Open market sales reported on this line occurred at a weighted average price of $130.25 (range $129.93 to $130.83).
F5Open market sales reported on this line occurred at a weighted average price of $131.55 (range $130.94 to $131.89).
F6Open market sales reported on this line occurred at a weighted average price of $132.44 (range $131.95 to $132.89).
F7Open market sales reported on this line occurred at a weighted average price of $133.03 (range $132.96 to $133.07).
F8Fully vested.